Compositions and methods for therapy of prostate cancer using drug combinations to target polyamine biosynthesis and related pathways
Provided are compositions and methods for treating prostate conditions. The methods involve administering to an individual in need thereof a composition that contains i) an inhibitor of methionine salvage pathway in prostate of the individual and ii) a polyamine analogue. The methods are for use in individuals who have been diagnosed with, or are suspected of having or at risk for developing androgen sensitive prostate cancer (AS-CaP), or Castration recurrent CaP (CR-CaP), or benign prostate hyperplasia (BPH). The disclosure includes use of inhibitors of methylthioadenosine phosphorylase (MTAP), and a polyamine analog that upregulates polyamine catabolism by increasing spermidine/spermine N1-acetyl transferase (SAT1) activity, such as methyl-thio-DADMe-Immucillin (MTDIA), and 1),N(11)-bisethylnorspermine (BENSpm), respectively. Pharmaceutical formulations that contain a combination of the inhibitor of the methionine salvage pathway and a polyamine analogue are included, as are kits that contain such agents.
1. A method that synergistically inhibits growth of prostate cancer (CaP) in an individual, the method comprising administering to the individual i) methylthio-DADMe-Immucillin (MTDIA) as an inhibitor of methionine salvage pathway in prostate of the individual;
and ii) a polyamine analogue selected from the group consisting of N(1),N(11)-bisethylnorspermine (BENSpm), alpha-difluoromethylornithine (DFMO), PG-11047, N 1 -ethyl-N 11 -[(cyclopropyl)methyl]-4,8,-diazaundecane (CPENSpm), aspirin, and combinations thereof.
2. The method of claim 1 , wherein the individual has been diagnosed with, or is suspected of having androgen sensitive prostate cancer (AS-CaP) or Castration recurrent CaP (CR-CaP).
3. The method of claim 1 , wherein the polyamine analogue comprises the BENSpm.
4. The method of claim 2 , wherein the methionine salvage pathway inhibitor is MTDIA and the polyamine analogue is BENSpm.
5. A method comprising contacting prostate tissue of an individual in need thereof with a combination of i) methylthio-DADMe-Immucillin (MTDIA) as an inhibitor of methionine salvage pathway in prostate of the individual;
and ii) a polyamine analogue selected from the group consisting of N(1),N(11)-bisethylnorspermine (BENSpm), alpha-difluoromethylornithine (DFMO), PG-11047, N 1 -ethyl-N 11 -[(cyclopropyl)methyl]-4,8,-diazaundecane (CPENSpm), aspirin, and combinations thereof, wherein contacting the prostate tissue with a combination of MTDIA and the polyamine analogue results in the synergistic inhibition of the growth of tissue in the prostate of the individual.
6. The method of claim 5 , wherein the individual is diagnosed with or is suspected of having prostate cancer (CaP) or benign prostate hyperplasia (BPH).
7. The method of claim 5 , wherein the polyamine analogue comprises the BENSpm.
8. The method claim 6 , wherein the methionine salvage pathway inhibitor is the MTDIA and the polyamine analogue is the BENSpm.
9. The method of claim 8 , wherein the individual has been diagnosed with, or is suspected of having BPH.
10. The method of claim 8 , wherein subsequent to the contacting the prostate tissue growth of prostate tissue is synergistically inhibited.
11. The method of claim 9 , wherein subsequent to the contacting the prostate tissue the size of the prostate gland in the individual is reduced.